PDGFRB and desmoid tumor: TKIs targeting VEGFR and/or PDGFR inhibit the growth and progression of desmoid tumors, as shown in phase 3 randomized, double-blind, placebo-controlled trials, including one trial investigating the use of sorafenib that showed an impressive PFS rate of 81% [102,103].